A PHASE 1 TRIAL OF ORAL RIDAFOROLIMUS (AP23573; MK-8669) IN COMBINATION WITH BEVACIZUMAB FOR PATIENTS WITH ADVANCED CANCERS

Friday, July 26, 2013